- Home
- STLA vs ROIV Comparison
STLA vs ROIV Comparison
Compare STLA & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STLA | ROIV |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | Netherlands | United Kingdom |
| Employees | N/A | 750 |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4B | 21.0B |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | STLA | ROIV |
|---|---|---|
| Price | $7.54 | $29.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $11.59 | ★ $28.94 |
| AVG Volume (30 Days) | ★ 15.3M | 4.5M |
| Earning Date | 02-26-2026 | 05-28-2026 |
| Dividend Yield | ★ 7.50% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,053,000.00 |
| Revenue This Year | $7.18 | N/A |
| Revenue Next Year | $3.50 | $744.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.28 | $10.59 |
| 52 Week High | $12.22 | $30.33 |
Technical Indicators
Market Signals| Indicator | STLA | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 59.74 |
| Support Level | $7.05 | $27.00 |
| Resistance Level | $8.27 | $30.26 |
| Average True Range (ATR) | 0.22 | 0.82 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 54.12 | 90.00 |
Price Performance
Historical ComparisonAbout STLA Stellantis N.V.
Stellantis was created out of the merger of US-based Fiat Chrysler Automobiles and French-based Peugeot in January 2021, resulting in the fourth-largest automotive original equipment manufacturer by vehicle sales. In 2024 it sold 5.5 million vehicles, 47%, 26% and 17% in Europe, North America, and South America, respectively. Its brands include Fiat, Jeep, Chrysler, Ram, Peugeot, Citroën, Opel, Alfa Romeo, and Maserati.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.